CAMBRIDGE, Mass. (April 8, 2020) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported its pipeline of MyoPro candidates continued to grow during the first quarter of 2020, with more than 700 candidates awaiting insurance reimbursement authorization as of March 31, 2020. This compares with 594 candidates as of December 31, 2019. In addition, the backlog of authorized units increased from 53 at the beginning of 2020 to 80 units as of March 31, 2020. Read more.